Related Experiment Video
Updated: May 27, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20
John V Heymach1, Helena A Yu2, Benjamin Besse3
1Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
There remains a significant unmet need for effective and tolerable treatments for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations in the first-line setting. First and later generation EGFR tyrosine kinase inhibitors (TKIs) have shown efficacy for common EGFR mutations; however, their effectiveness against ex20ins mutations is limited, and platinum-based chemotherapy remains part of the standard of care. Data suggest that combining chemotherapy with EGFR inhibitors offers promise for EGFR ex20ins-mutated NSCLC. REZILIENT3 is an ongoing phase III study evaluating the efficacy and safety of zipalertinib (an orally available, irreversible EGFR-TKI) plus first-line standard-of-care platinum-based chemotherapy with chemotherapy alone in previously untreated patients with nonsquamous NSCLC harboring EGFR ex20ins mutations.Clinical Trial Registration: NCT05973773 (ClinicalTrials.gov).
Insights
First-line treatment for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations is being studied. The REZILIENT3 trial investigates zipalertinib combined with chemotherapy versus chemotherapy alone for improved outcomes.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins) mutations presents a significant unmet need for effective first-line therapies.
- Standard treatments like chemotherapy show limited efficacy for this specific mutation subtype.
- Current EGFR tyrosine kinase inhibitors (TKIs) are less effective against EGFR ex20ins mutations compared to other EGFR alterations.
Purpose of the Study:
- To evaluate the efficacy and safety of zipalertinib in combination with platinum-based chemotherapy as a first-line treatment for NSCLC patients with EGFR ex20ins mutations.
- To compare the combination therapy against standard chemotherapy alone in this patient population.
Main Methods:
- The REZILIENT3 study is a phase III clinical trial.
- It enrolls previously untreated patients with nonsquamous NSCLC harboring EGFR ex20ins mutations.
- Participants are randomized to receive either zipalertinib plus chemotherapy or chemotherapy alone.
Main Results:
- Data are pending as the study is ongoing.
- The primary endpoints are efficacy and safety of the combination therapy.
Conclusions:
- The study aims to establish a new standard of care for first-line treatment of NSCLC with EGFR ex20ins mutations.
- Positive results could offer a more effective and tolerable therapeutic option for patients.
- Combination therapy of EGFR inhibitors with chemotherapy shows promise for this challenging NSCLC subtype.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
